Prophylactic Azithromycin for Bronchiectasis, a randomised controlled trial to assess whether azithromycin reduces exacerbation frequency, improves health-related quality of life and increases lung function.

None listed

Bronchiectasis is a neglected health problem in New Zealand, particularly amongst Maori and Pacific peoples. It is a debilitating disease characterised by repeated respiratory infections. Azithromycin is a unique antibiotic with anti-inflammatory properties that has been shown to be effective as prophylaxis in cystic fibrosis. The aim of this study is to assess the effect of long term azithromycin in adult patients with non-cystic fibrosis bronchiectasis. It will be the first randomised, controlled trial in this important patient group and will provide data on clinically relevant outcome measures. The benefits to patients are expected to include improved quality of life, prevention or delay in decline of lung function and reduced acute healthcare utilisation and costs. Importantly, these benefits will also have a substantial impact on the health of Maori and Pacific peoples. We have a rare and unparalleled opportunity to undertake this study because of the high prevalence of bronchiectasis in NZ.